Compare Domino's Pizza, Inc. (DPZ) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Novo Nordisk A/S — how do they compare? Domino's Pizza, Inc. trades at $309.85 (market cap $10.31B), while Novo Nordisk A/S trades at $49.07 (market cap $214.94B). The key difference: Novo Nordisk A/S is far larger — about 20.8× Domino's Pizza, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.67%). Which is the better fit depends on your goals.
| DPZ | NVO | |
|---|---|---|
Market Cap | $10.31B | $214.94B |
Sector | Consumer Cyclical | Health |
52-Week High | $485.53 | $71.70 |
52-Week Low | $282.89 | $35.29 |
Enterprise Value | $15.21B | $233.91B |
Dividend Yield | 2.57% | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $309.85, up 3.47% today, with a neutral technical signal and bearish moving averages. The company reported Q1 2026 EPS of $4.13, missing expectations, but maintains strong profitability with a net margin of 11.89%. Recent news includes CEO succession and new product launches, while analyst consensus remains bullish with a $380.31 price target.
DPZ offers steady growth and a 2.66% dividend yield, but faces risks from slowing same-store sales and high debt. The stock's valuation at 17.84x P/E is reasonable, yet competitive pressures and macroeconomic headwinds warrant caution. Upside potential exists if Q2 earnings beat expectations and new leadership reinvigorates growth.
Novo Nordisk (NVO) trades at $49.28, down 0.4% on the day, with strong technical momentum indicated by bullish moving averages and a neutral RSI near 63. The company demonstrates robust fundamentals with a P/E of 11.83, net income margin of 37.2%, and consistent earnings beats in recent quarters. Recent news highlights competitive strength in GLP-1 drugs, including Wegovy pill adoption outpacing Eli Lilly's offering.
Outlook remains positive given analyst consensus of 57.9% buy ratings and intrinsic value estimates near $90, though risks include prescription slowdown concerns and rising debt-to-asset ratios. The stock presents a growth opportunity in pharmaceuticals with manageable near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
